50 results about "Metastasis Suppression" patented technology

Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.

The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics

The present invention relates to a pharmaceutical composition for the prevention and the treatment of cancers containing diaryl-isoxazole derivatives as an effective ingredient. Diaryl-isoxazole derivatives of the present invention inhibit metastasis of breast cancer cell lines and angiogenesis, so that they can be produced as a metastasis inhibitor and further as a pharmaceutical composition for the prevention and the treatment of angiogenesis related diseases including cancers, rheumatoid arthritis, psoriasis, or angiogenesis diseases caused in eyeball, etc.

The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes, which contains natural minerals and the water extracted therefrom as active ingredients. More particularly, at least one mineral selected from the group consisting of lizardite, antigorite, brucite, magnesite, dolomite, talc, clinochlore, calcite, hornblende, and phologopite, and water which is extracted from the minerals and the quality of which is suitable for the standards of drinking water, contain a significantly large amount of rare earth elements, generate a large amount of far-infrared radiation and anions to enhance and promote health, block various forms of harmful radiation such as water vein waves and electromagnetic waves, stimulate the activity of the metabolism, and have the effects of remarkably inhibiting and reducing blood glucose for type 1 and type 2 diabetes. Therefore, the mineral and the water extracted therefrom can be effectively used in developing: a pharmaceutical composition for the purpose of preventing and treating diabetes, and a healthy food composition having the same purpose; a pharmaceutical composition for the purpose of preventing and treating cancer due to having the remarkable effects of inhibiting tumors from growing or metastasizing in the case of leukemia, colorectal cancer, stomach cancer, lung cancer, and skin cancer, and a healthy food composition having the same purpose; and a pharmaceutical composition for antibacterial purposes due to having highly antibacterial effects against colon bacillus and pseudomonas aeruginosa, as well as a composition to be externally applied to the skin and a cosmetic composition having the same purpose.

The invention relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines, belongs to the field of biopharmaceutical research, and particularly relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines. The inventor firstly finds that the PNO1 can be used as an esophagus cancer treatment target point. The PNO1 inhibitor can restrain the proliferation rate of esophagus cancer cells, can restrain the cloning and forming capacity of the esophagus cancer cells, can promote esophagus cancer apoptosis, can restrain esophagus cancer cell migration, can restrain esophagus cancer cell transfer, and can restrain esophagus cancer cell invasion and transfer, so as to treat esophagus cancer, and a new direction is opened up for treatment of esophagus cancer.

The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics.

The invention discloses a method for inhibiting the growth and metastasis of solid tumor cells and a special pharmaceutical composition, and belongs to the field of animal cell proliferation and transformation. When ovarian cancer HEY cells or breast cancer MDA-MB-231 cells are induced, a culture medium is replaced after acting in high-concentration CoCl2, and after the cells are recovered, the treatment is repeated twice to obtain a sufficient number of cells with high invasion and metastasis ability; and the obtained cells are cultured in a culture medium without CoCl2, then the removed culture medium is added with a pharmaceutical composition prepared from dimethyl sulfoxide, dexamethasone, rosiglitazone, 3-isobutyl-1-methylxanthine for in-vitro induction, and when obvious lipid droplets are formed in tumor cell plasma, it indicates that the tumor cells have adipose differentiation. The method is designed to induce the tumor cell adipose differentiation and the purpose of inhibitingtumor cell growth is achieved. It is confirmed by animal experiments that the method is expected to be used for clinical treatment and metastasis inhibition of human solid tumors.

[Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis.Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.

The present invention provides a therapeutic agent for a tumor, particularly a therapeutic agent for drug-resistant cancer, an agent for suppression or prophylaxis of tumor metastasis, and an agent for suppression or prophylaxis of cancer recurrence, containing a nucleic acid containing miR27b or a nucleotide having a nucleotide sequence having an identity of 70% or more with the nucleotide sequence shown by SEQ ID NO: 1 and having a function equivalent to miR27b.

The invention relates to RNA-binding protein PNO1 capable of being used as a lung cancer diagnosis target and treatment target, and particularly discloses overexpression of the RNA-binding protein PNO1 in lung cancer cells. Overexpression of the RNA-binding protein PNO1 in the lung cancer cells can promote proliferation of the lung cancer cells, and is related to short prognosis survival time of lung cancer patients. By reducing expression of the PNO1, growth and metastasis of the lung cancer cells are inhibited, and apoptosis of the lung cancer cells is increased, so that inhibition of expression of the PNO1 represents a novel strategy for treating lung cancer.

Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux.

The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.

The present invention provides a complex comprising an antibody that targets an exosome surface antigen or an antibody fragment of the antibody and a suppressor of a gene or an expression product of the gene, wherein the antibody or the antibody fragment and the suppressor of the gene or the expression product of the gene are covalently bound to each other directly or through a linker or are non-covalently bound to each other.

The invention discloses a supramolecular nano-drug for targeted activation of a Hippo pathway in cancer cells and application of the supramolecular nano-drug. The amphiphilic compound Fmoc-S (FA) FFYSV-SS-PEG (FASP) is obtained by connecting a hydrophobic oligopeptide fragment and a hydrophilic polyethylene glycol fragment, which contain double drug components, through a disulfide bond, and the amphiphilic compound Fmoc-S (FA) FFYSV-SS-PEG (FASP) is obtained. The compound can be self-assembled through intermolecular non-covalent interaction to form an inactive nano prodrug, the nano prodrug is subjected to morphological transformation after being taken by cancer cells, bioactive peptide nanofibers are formed in situ, and flufenamic acid (FA) is released, so that a disordered Hippo pathway is activated to be used for tumor chemoradiotherapy combined treatment and metastasis inhibition, and the compound has the characteristics that the synthesis is simple, the cost is low, and the compound is suitable for large-scale industrial production. The repeatability is high, the biocompatibility is good, and the clinical transformation potential is great. Meanwhile, compared with free FA, the supramolecular nano-drug obtained by the invention can be delivered through covalent linkage and released in situ in a responsive manner, so that the growth inhibition effect of FA on tumor cells is remarkably improved, the toxic and side effects of FA on normal cells are reduced, and the supramolecular nano-drug has good clinical transformation and application prospects.

A novel domain of Aggrus involved in the binding to CLEC-2 was searched for, and monoclonal antibodies recognizing the domain were obtained. The newly found PLAG4 domain is important for Aggrus binding to CLEC-2. Monoclonal antibodies recognizing this region were further developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors using these antibodies.

The invention related to the use of high-density loss of heterozygosity (LOH) mapping in lung adenocarcinoma to identify intragenic LOH and driver mutations in different domains of ALK resulted in enhanced tumor growth in xenografted mouse. Mutant (H694R and E1384K) ALKs showed activation of Y1604 ALK and downstream AKT, STAT3 and ERK signaling pathways. Increases of oncogenic signalings resulted in enhanced cell proliferation, colony-formation, cell-migration and tumor-growth in xenografted mouse. Western blot and immunohistochemistry analysis using antibody against phospho-Y1604 ALK on 11 lung cancer cell-lines and 263 cancer specimens indicated ALK activation in all lung cancers regardless of tumor stages. Treating mutant-bearing mice with ALK inhibitor WHI-P 154 resulted in tumor shrinkage, metastasis suppression, and improved survival. Hyperphosphorylation of Y1604 ALK occurred early and continuously throughout tumor progression and could be used as a biomarker to detect lung cancer. Oncogenic ALK point mutations could be treatment targets for lung cancer.

Provided is a metastasis suppressing agent containing a HSP47 inhibitor.

The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.

The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.

The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.

The invention provides a polymer nano-micelle entrapped with two drugs as well as a preparation method and application of the polymer nano-micelle. The polymer nano-micelle is prepared from a methoxy polyethylene glycol-polycaprolactone block copolymer mPEG-PCL, curcumin and adriamycin, the micelle is non-toxic, small in particle size, stable, high in encapsulation efficiency and controllable in drug release behavior, compared with a micelle entrapped with a single drug, the toxicity and apoptosis promoting effect on 4T1 breast cancer cells are obviously enhanced, and the drug release behavior is controllable. Tumor growth and metastasis can be effectively inhibited, and tumor angiogenesis is inhibited. According to the invention, the biodegradable methoxy polyethylene glycol-polycaprolactone (mPEG-PCL) polymer nano-micelle is used for simultaneously entrapping adriamycin and curcumin, the preparation process is simple, no surfactant or additive is used in the preparation process, the safety in clinical application is ensured, and the nano-micelle has an excellent clinical application prospect.

The invention discloses a genetically engineered antigen presenting extracellular vesicle, the antigen presenting extracellular vesicle loads a tumor associated antigen and overexpresses an immunomodulatory molecule and a single-chain antibody at the same time, and a vaccine preparation for tumor treatment is prepared based on the antigen presenting extracellular vesicle. Particularly, the compound has outstanding performance in inhibition of tumor metastasis, and has huge potential in serving as a new-generation drug loading platform. The genetically engineered extracellular vesicles constructed by the invention not only maintain the antigen presentation capability, but also target tumor antigens, and regulate solid tumor immune microenvironment so as to effectively activate T cells in tumors to exert anti-tumor activity, and finally realize tumor killing and metastasis inhibition functions.

The invention discloses a method for ferrocene-berberine / indomethacin@glucose oxidase@hyaluronic acid self-assembly targeting anti-cancer nano-medicine, by designing ferrocene-berberine-coupled drug molecules, and Indomethacin together induces the self-assembly of glucose oxidase, which is then encapsulated by hyaluronic acid to obtain anticancer nano-drugs. The present invention provides a preparation method of the ferrocene-berberine / indomethacin@glucose oxidase@hyaluronic acid nanomedicine and its application in cancer treatment. The nano-medicine provided by the invention can be delivered in a targeted manner, and exhibits significant inhibitory effects on growth and metastasis of liver cancer cells.

The invention belongs to the technical field of biological medicine, and relates to application of a VGF gene in treatment of metastatic prostate cancer. The invention discloses application of a VGF gene inhibitor in preparation of prostatic cancer drugs. It is found for the first time that the VGF can promote invasion and metastasis of the prostate cancer, the VGF has higher expression in prostate cancer tissue with higher malignancy degree, and generation and development of the prostate cancer can be inhibited by inhibiting the VGF. A VGF small-molecule inhibitor siRNA is prepared, so that prostatic cancer is treated, metastasis of the prostatic cancer is inhibited, and a PI3K / AKT signal channel is inhibited. The invention provides a new thought for further researching the pathogenesis of prostatic cancer and the function of the VGF gene, and provides a new direction for the development of prostatic cancer drugs.

Provided is a metastasis suppressing agent containing a HSP47 inhibitor.

The present invention relates to a pharmaceutical composition which is for preventing or treating brain cancer and includes at least 99% of a crystal polymorph of tetraarsenic hexoxide a (As4O6-a), and to a method for preparing same. A composition according to the present invention exhibits excellent cancer cell proliferation inhibition and metastasis inhibition effects, and thus may be usefully used as an anti-cancer agent.